Background
PRKAG2 syndrome (PS) is a rare, early-onset autosomal dominant inherited disease caused by mutations in PRKAG2, the gene encoding the regulatory c2 subunit of adenosine monophosphate-activated protein kinase (AMPK). PRKAG2 syndrome is associated with many cardiac manifestations, including pre-excitation, supraventricular and ventricular arrhythmias, left ventricular hypertrophy, and chronotropic incompetence frequently leading to early pacemaker placement. 1 The left ventricular hypertrophy is secondary to abnormal glycogen storage 2 and activation of hypertrophic signalling pathways. 3, 4 Interestingly, a meta-analysis of genome-wide association data in subjects with chronic kidney disease (CKD) identified a susceptibility locus in an intron of PRKAG2, 5 which has been replicated in other studies. 6, 7 However, CKD has not been reported in patients with PS
Learning points
• PRKAG2 syndrome (PS) is a rare, early-onset autosomal dominant inherited disease caused by mutations in PRKAG2, the gene encoding the regulatory c2 subunit of adenosine monophosphate-activated protein kinase (AMPK).
• PRKAG2 syndrome is associated with many cardiac manifestations, including pre-excitation, supraventricular and ventricular arrhythmias, left ventricular hypertrophy, and chronotropic incompetence frequently leading to early pacemaker placement.
• While chronic kidney disease has not been directly linked to PS, there are potential mechanisms by which AMPK activation could result in injury to B cells or glomerular cells. Our patient had PS and developed biopsy-proven immunoglobulin A nephropathy.
or mutations in PRKAG2. We present a case of PS with immunoglobulin A (IgA) nephropathy (IGAN).
Timeline
Case presentation At a follow-up evaluation by her cardiologist, she denied palpitations, syncope, or falls. Her pulse was 70 b.p.m., and her blood pressure was 115/84 mmHg. Her jugular venous pressure was normal, and her exam revealed normal heart sounds. Her ECG was consistent with a left anteroseptal accessory pathway.
The following year, it was discovered that the patient's Mother also suffered from Wolff-Parkinson-White syndrome and had a PRKAG2 mutation. In addition, her maternal grandfather reportedly had a history of 'hypertrophic cardiomyopathy', atrial fibrillation, and complete heart block requiring permanent pacemaker implantation. Upon evaluation by a cardiac geneticist, the patient was confirmed to have inherited the PRKAG2 mutation. It was recommended that she continue to receive long-term cardiology surveillance with serial echocardiograms, treadmill exercise stress tests, and ECGs.
Over the next 8 years, the patient was maintained on daily bisoprolol 1.25 . By the age of 35 years, her creatinine had risen to 107 mmol/L, her blood urea nitrogen (BUN) was 7.3 mmol/L (normal range 2.1-87.1 mmol/L), and her estimated GFR was 61 mL/min/1.73 m 2 . A urinalysis showed 2þ proteins and 3þ glucose. On follow-up evaluation by a nephrologist a few months later, her laboratories were notable for a creatinine of 151 mmol/L, BUN 10.5 mmol/L, and GFR 51 mL/min/1.73 m 2 . Her urine protein/creatinine ratio was 75. Her parathyroid hormone was reportedly 75 pg/mL (normal range 15-65 pg/mL). Her C3 and C4 levels were normal. An abdominal ultrasound showed normal kidneys bilaterally. A renal biopsy established a diagnosis of IGAN (Figures 2-5) , with mild-to-moderate mesangioproliferative activity and evidence of some chronicity. Focal, global, and segmental glomerulosclerosis, and focal interstitial fibrosis/tubular atrophy was present. Also noted in the renal parenchyma were vacuolated tubular cells and interstitial foam cells, which have been associated with subsets of genetic abnormalities including glycogen storage diseases, but are not usually found in IGAN. Additionally, her blood pressure was 143/83 mmHg. She was started on ramipril 2.5 mg daily for both her hypertension and proteinuria.
She remains stable 10 years and 4 months since her initial diagnosis from both cardiac and renal perspectives.
Discussion
Since its discovery and first report in 2001, 8 most of the attention in patients with PS has focused on the cardiac manifestations described above. Genome-wide association studies have identified that the rs7805747 SNP in an intron of PRKAG2 is associated with CKD and decreased GFR. Furthermore, differential methylation of PRKAG2 in DNA from blood was noted in CKD subjects. 9 Other hereditary glycogen storage diseases are associated with renal disease, such as renal tubular dysfunction. 10 Gene-targeted knock-in mice with the Arg531Gly mutation in Prkag2 exposed to a high fat diet showed severe kidney injury characterized by glycogen accumulation, inflammation, apoptosis, cyst formation, and impaired renal function.
11
Immunoglobulin A nephropathy is characterized by deposits of IgA 1 in the glomeruli. This process may be the consequence of deposition of circulating immune complexes or the formation of immune complexes in situ in the glomeruli. 12 These complexes involve a reaction between abnormally glycosylated IgA 1 and an auto-antibody that recognizes carbohydrate side chains of IgA 1 that are deficient in galactose.
The mechanisms by which mutations in PRKAG2 may lead to IGAN or CKD are unclear. Mutations in PRKAG2 generally lead to inappropriate activation of AMPK. Recent studies suggest that AMPK may contribute to renal disease. AMPK appears to activate fibroblasts and could induce renal fibrosis in obstructive or ischaemia-reperfusion injury. 13 AMPK inhibits Akt and activates the FOXO3a 17 However, inappropriate activation of AMPK secondary to PRKAG2 mutations may be deleterious. The presence of vacuolated tubular cells and interstitial foam cells on renal biopsy suggests that AMPK activation was directly contributing to the nephropathy, since similar vacuolation is seen in cardiomyocytes in the setting of PRKAG2 mutations. 18 However, renal impairment seemed to lag behind the cardiac manifestations in this patient. We speculate that kidneys have a greater physiological reserve than the heart, so that significant renal impairment must occur before changes in serum creatinine are evident.
Although the mechanisms leading from PRKAG2 mutations to IGAN remain speculative, the presence of two fairly rare diseases in a young woman suggests a possible link that warrants further investigation.
Supplementary material
Supplementary material is available at European Heart Journal -Case Reports online.
Slide sets: A fully edited slide set detailing this case and suitable for local presentation is available online as Supplementary data.
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